Current Cancer Drug Targets

Ruiwen Zhang 
Texas Tech University Health Sciences Center
1300 Coulter Drive
Amarillo, TX 79106


Non-Homologous DNA End Joining in Anticancer Therapy

Author(s): Elzbieta Pastwa and Mariusz Malinowski

Affiliation: Molecular Genetics Department,Medical University of Lodz, Mazowiecka 6/8, 92-215 Lodz, Poland.


Non-homologous DNA end joining (NHEJ) is the major pathway for the repair of double-strand breaks (DSBs) in human cells. Proteins involved in NHEJ pathway can become molecular targets in the treatment of cancer. Inhibition of this pathway leads to radio- and chemosensitization of cancer cells. This review will focus on the new therapeutic strategies for NHEJ pathway inhibition and their application in anticancer therapy.

Keywords: Non-homologous DNA end joining, NHEJ, DNA double-strand breaks, DSBs, DNA-dependent protein kinase, DNA-PK, chemosensitization, radiosensitization

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [243 - 250]
Pages: 8
DOI: 10.2174/156800907780618284